What a busy week as the second quarter came to a close with a flurry of data announcements. Catch up on all the action with the latest edition of the Biotech Tweets of the Week, curated by @23aloha and @BioDueDiligence. This installment features:
-GW Pharma delivers another win with cannabis drug $GWPH
-Regulus falls farther behind the HCV field with clinical hold $RGLS
-F is for fail... Bad data from $CYAD $AMPE $MRNS $GALE
-Another bump in the road for Esperion's cholesterol drug $ESPR
-Tesaro's ovarian cancer data spurs PARP resurgence $TSRO
-On the topic of debt $ICPT et al
-As seen on the stream (the best of everything else)
http://www.biotechduediligence.com/tweets2016-07-01.html
-GW Pharma delivers another win with cannabis drug $GWPH
-Regulus falls farther behind the HCV field with clinical hold $RGLS
-F is for fail... Bad data from $CYAD $AMPE $MRNS $GALE
-Another bump in the road for Esperion's cholesterol drug $ESPR
-Tesaro's ovarian cancer data spurs PARP resurgence $TSRO
-On the topic of debt $ICPT et al
-As seen on the stream (the best of everything else)
http://www.biotechduediligence.com/tweets2016-07-01.html
RSS Feed
